Nexalin Technology, Inc. announced on April 2, 2025, the successful enrollment of the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System. Treatment of these first patients with the Nexalin HALO™ headset commenced this week.
This milestone signifies the transition from patient recruitment to active participation in the study, which aims to evaluate Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology. The HALO™ Clarity devices are being assessed as a potential treatment for mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) in military personnel and the civilian population.
CEO Mark White stated that this is a pivotal step forward in initiating treatments for civilians and veterans struggling with TBI and PTSD. The study is designed to gather comprehensive data on the impact of DIFS™ technology, contributing to Nexalin’s broader regulatory and commercialization strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.